Diagnostic and predictive value of skin testing in platinum salt hypersensitivity.
BACKGROUND
Hypersensitivity reactions to platinum salts are potentially lethal adverse events in chemotherapy, and often require its discontinuation. Several preventive procedures have been proposed: premedication, desensitization regimens, or replacement with a different platinum salt.


OBJECTIVE
We therefore assessed the value of skin tests with platinum salts. A positive result would confirm their responsibility in hypersensitivity reaction, whereas a negative result would identify candidates for continuation of therapy using a different platinum salt.


METHODS
Patch tests, prick tests, and intradermal tests with cisplatin, carboplatin, and oxaliplatin were performed in 21 patients.


RESULTS
Skin tests were positive in 14 of 21 cases. Prick tests were positive in 5 cases with the suspected platinum salt. Intradermal tests were positive in 12 of 19 cases, always when the hypersensitivity occurred less than 2 hours after infusion. Cross-reactions were observed in 4 cases. Delayed readings of skin tests at 24 hours and 48 hours were positive in 3 patients. Patch tests were negative in all the 21 patients tested. Replacement with another platinum salt was performed in 13 patients using one that gave a negative skin test. A relapse of symptoms occurred in 1 patient.


CONCLUSIONS
Intradermal tests are particularly indicated for the diagnosis of immediate hypersensitivity reaction. Their good negative predictive value allows safe retreatment by detecting a potential cross-reaction.


CONCLUSIONS
The frequency of cross-reactions among cisplatin, carboplatin, and oxaliplatin has not been clearly established. Skin tests allow different platinum salts to be given and avoid discontinuation of chemotherapy.
Leguy-Seguin
Vanessa
V
Dermatology Department, University Hospital, Dijon Cedex, France.
Jolimoy
Genevieve
G
Coudert
Bruno
B
Pernot
Corine
C
Dalac
Sophie
S
Vabres
Pierre
P
Collet
Evelyne
E
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000276:immunology*; D016190:Carboplatin / Q000276:immunology; D002945:Cisplatin / Q000276:immunology; D003429:Cross Reactions; D004342:Drug Hypersensitivity / Q000175:diagnosis*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000276:immunology; D000077150:Oxaliplatin; D010984:Platinum / Q000276:immunology*; D011379:Prognosis; D011446:Prospective Studies; D012492:Salts / Q000276:immunology*; D012882:Skin Tests
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D012492:Salts; D000077150:Oxaliplatin; D010984:Platinum; D016190:Carboplatin; D002945:Cisplatin